News Results
There are 792,420 News Results
May 2, 2024
Owens Corning (NYSE: OC), a leader in global building and construction materials, and Masonite International Corporation (“Masonite”) (NYSE: DOOR), a leading global provider of interior and exterior doors and door...
May 7, 2024
Otter Tail Corporation (Nasdaq: OTTR) today announced financial results for the quarter ended March 31, 2024. SUMMARY Diluted earnings per share increased 19% to $1.77 per share compared to the...
May 8, 2024
Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment, today announced first quarter 2024 financial...
May 9, 2024
Unifi, Inc. (NYSE: UFI) (together with its consolidated subsidiaries, “UNIFI”), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, today released operating results for...
May 15, 2024
Owens Corning (NYSE: OC), a leader in global building and construction materials, and Masonite International Corporation (“Masonite”) (NYSE: DOOR), a leading global provider of interior and exterior doors and door...
Jan 30, 2024
DENVER, Jan. 30, 2024 /PRNewswire/ -- M.D.C. Holdings, Inc. (NYSE: MDC), announced results for the quarter and full year ended December 31, 2023. As previously announced on January 18, 2024,...
Feb 1, 2024
MENLO PARK, Calif., Feb. 1, 2024 /PRNewswire/ -- Meta Platforms, Inc. (Nasdaq: META) today reported financial results for the quarter and full year ended December 31, 2023. "We had a...
Feb 7, 2024
-- Full year 2023 revenues were $192.6 million -- PONVORY(®) acquisition completed in Q4 2023 and transition ongoing -- 3 FDA PDUFA target action dates in 2024 -- Ended 2023...
Feb 14, 2024
-- Delivers record full year 2023 financial and operating results -- Reports fourth quarter volume of over 2.2 billion gallons, highest in the Partnership's history -- Reaffirms full year 2024...
Feb 15, 2024
- Priority review designation is based on results from the Phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab significantly extended overall survival and progression free survival compared to...
